Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, ...

德国汉堡 - 专注于药物发现和开发的制药公司Evotec SE今天向美国证券交易委员会提交了一份临时公告，回应了最近的媒体猜测。这家在法兰克福证券交易所以EVO为股票代码上市的公司，对有关其业务运营的报道作出了澄清。 在公告中，Evotec的首席执行官Christian Wojczewski表示："我们经常评估潜在的战略机会以提升股东价值，并将继续这样做。"Wojczewski强调，虽然公司愿意探 ...

Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec .

Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR ...

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...

据知情人士透露，私募股权公司Triton Partners正在考虑收购德国生物科技公司Evotec (EVO.US)。此前，这家公司已成为Evotec的最大股东之一。 知情人士表示，这家投资公司一直在寻求与Evotec高管会面，以探讨潜在的收购事宜。根据最新的美国监管文件，Triton上周通过一系列交易将其在Evotec的股份提高到9.99%。

Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall around ...

圣地亚哥 - Halozyme Therapeutics, Inc. (NASDAQ: HALO)提出了一项非约束性提议,以每股11.00欧元的现金价格收购Evotec SE (NASDAQ: EVO),这将使Evotec的股权价值约为20亿欧元。这一报价相对于2024年10月15日Triton Partners开始累积股份之前的Evotec股价有显著溢价。 此次收购将把Halozyme的药物输送 ...

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...

Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

智通财经APP获悉，据知情人士透露，私募股权公司Triton Partners正在考虑收购德国生物科技公司Evotec(EVO.US)。此前，这家公司已成为Evotec的最大股东之一。

Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion). Shares traded ...